
Global Recombinant Erythropoietin Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Recombinant Erythropoietin market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Recombinant Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Recombinant Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Recombinant Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Recombinant Erythropoietin include 3SBio Group, Biocon Limited, Celltrion, Inc, Dr. Reddy's Laboratories Ltd, F. Hoffmann-La Roche Ltd, Intas Pharmaceuticals Ltd, Kyowa Hakko Kirin, LG Life Sciences Ltd and Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Erythropoietin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Erythropoietin.
The Recombinant Erythropoietin market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Erythropoietin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Recombinant Erythropoietin Segment by Company
3SBio Group
Biocon Limited
Celltrion, Inc
Dr. Reddy's Laboratories Ltd
F. Hoffmann-La Roche Ltd
Intas Pharmaceuticals Ltd
Kyowa Hakko Kirin
LG Life Sciences Ltd
Amgen
Roche
Johnson & Johnson
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Recombinant Erythropoietin Segment by Type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)
Recombinant Erythropoietin Segment by Application
Chronic Kidney Disease
Cancer Related Anemia
Others
Recombinant Erythropoietin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Erythropoietin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Erythropoietin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Erythropoietin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Recombinant Erythropoietin companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
According to APO Research, The global Recombinant Erythropoietin market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Recombinant Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Recombinant Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Recombinant Erythropoietin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Recombinant Erythropoietin include 3SBio Group, Biocon Limited, Celltrion, Inc, Dr. Reddy's Laboratories Ltd, F. Hoffmann-La Roche Ltd, Intas Pharmaceuticals Ltd, Kyowa Hakko Kirin, LG Life Sciences Ltd and Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Erythropoietin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Erythropoietin.
The Recombinant Erythropoietin market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Erythropoietin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Recombinant Erythropoietin Segment by Company
3SBio Group
Biocon Limited
Celltrion, Inc
Dr. Reddy's Laboratories Ltd
F. Hoffmann-La Roche Ltd
Intas Pharmaceuticals Ltd
Kyowa Hakko Kirin
LG Life Sciences Ltd
Amgen
Roche
Johnson & Johnson
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Recombinant Erythropoietin Segment by Type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)
Recombinant Erythropoietin Segment by Application
Chronic Kidney Disease
Cancer Related Anemia
Others
Recombinant Erythropoietin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Erythropoietin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Erythropoietin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Erythropoietin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Recombinant Erythropoietin companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Table of Contents
100 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Recombinant Erythropoietin Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global Recombinant Erythropoietin Market Size by Region (2020-2031)
- 1.4.1 Global Recombinant Erythropoietin Market Size by Region (2020-2025)
- 1.4.2 Global Recombinant Erythropoietin Market Size by Region (2026-2031)
- 1.5 Key Regions Recombinant Erythropoietin Market Size (2020-2031)
- 1.5.1 North America Recombinant Erythropoietin Market Size Growth Rate (2020-2031)
- 1.5.2 Europe Recombinant Erythropoietin Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific Recombinant Erythropoietin Market Size Growth Rate (2020-2031)
- 1.5.4 South America Recombinant Erythropoietin Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa Recombinant Erythropoietin Market Size Growth Rate (2020-2031)
- 2 Recombinant Erythropoietin Market by Type
- 2.1 Type Introduction
- 2.1.1 rhEPO
- 2.1.2 Erythropoiesis-Stimulating Agents (ESA)
- 2.2 Global Recombinant Erythropoietin Market Size by Type
- 2.2.1 Global Recombinant Erythropoietin Market Size Overview by Type (2020-2031)
- 2.2.2 Global Recombinant Erythropoietin Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global Recombinant Erythropoietin Market Size Forecasted by Type (2026-2031)
- 2.3 Global Recombinant Erythropoietin Market Size by Regions
- 2.3.1 North America Recombinant Erythropoietin Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe Recombinant Erythropoietin Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific Recombinant Erythropoietin Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America Recombinant Erythropoietin Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa Recombinant Erythropoietin Market Size Breakdown by Type (2020-2025)
- 3 Recombinant Erythropoietin Market by Application
- 3.1 Type Introduction
- 3.1.1 Chronic Kidney Disease
- 3.1.2 Cancer Related Anemia
- 3.1.3 Others
- 3.2 Global Recombinant Erythropoietin Market Size by Application
- 3.2.1 Global Recombinant Erythropoietin Market Size Overview by Application (2020-2031)
- 3.2.2 Global Recombinant Erythropoietin Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global Recombinant Erythropoietin Market Size Forecasted by Application (2026-2031)
- 3.3 Global Recombinant Erythropoietin Market Size by Regions
- 3.3.1 North America Recombinant Erythropoietin Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe Recombinant Erythropoietin Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific Recombinant Erythropoietin Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America Recombinant Erythropoietin Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa Recombinant Erythropoietin Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 Recombinant Erythropoietin Industry Trends
- 4.2 Recombinant Erythropoietin Industry Drivers
- 4.3 Recombinant Erythropoietin Industry Opportunities and Challenges
- 4.4 Recombinant Erythropoietin Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by Recombinant Erythropoietin Revenue (2020-2025)
- 5.2 Global Recombinant Erythropoietin Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global Recombinant Erythropoietin Key Company Headquarters & Area Served
- 5.4 Global Recombinant Erythropoietin Company, Product Type & Application
- 5.5 Global Recombinant Erythropoietin Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Recombinant Erythropoietin Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Recombinant Erythropoietin Players Market Share by Revenue in 2024
- 5.6.3 2024 Recombinant Erythropoietin Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 3SBio Group
- 6.1.1 3SBio Group Comapny Information
- 6.1.2 3SBio Group Business Overview
- 6.1.3 3SBio Group Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 3SBio Group Recombinant Erythropoietin Product Portfolio
- 6.1.5 3SBio Group Recent Developments
- 6.2 Biocon Limited
- 6.2.1 Biocon Limited Comapny Information
- 6.2.2 Biocon Limited Business Overview
- 6.2.3 Biocon Limited Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 Biocon Limited Recombinant Erythropoietin Product Portfolio
- 6.2.5 Biocon Limited Recent Developments
- 6.3 Celltrion, Inc
- 6.3.1 Celltrion, Inc Comapny Information
- 6.3.2 Celltrion, Inc Business Overview
- 6.3.3 Celltrion, Inc Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 Celltrion, Inc Recombinant Erythropoietin Product Portfolio
- 6.3.5 Celltrion, Inc Recent Developments
- 6.4 Dr. Reddy's Laboratories Ltd
- 6.4.1 Dr. Reddy's Laboratories Ltd Comapny Information
- 6.4.2 Dr. Reddy's Laboratories Ltd Business Overview
- 6.4.3 Dr. Reddy's Laboratories Ltd Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 Dr. Reddy's Laboratories Ltd Recombinant Erythropoietin Product Portfolio
- 6.4.5 Dr. Reddy's Laboratories Ltd Recent Developments
- 6.5 F. Hoffmann-La Roche Ltd
- 6.5.1 F. Hoffmann-La Roche Ltd Comapny Information
- 6.5.2 F. Hoffmann-La Roche Ltd Business Overview
- 6.5.3 F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Product Portfolio
- 6.5.5 F. Hoffmann-La Roche Ltd Recent Developments
- 6.6 Intas Pharmaceuticals Ltd
- 6.6.1 Intas Pharmaceuticals Ltd Comapny Information
- 6.6.2 Intas Pharmaceuticals Ltd Business Overview
- 6.6.3 Intas Pharmaceuticals Ltd Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.6.4 Intas Pharmaceuticals Ltd Recombinant Erythropoietin Product Portfolio
- 6.6.5 Intas Pharmaceuticals Ltd Recent Developments
- 6.7 Kyowa Hakko Kirin
- 6.7.1 Kyowa Hakko Kirin Comapny Information
- 6.7.2 Kyowa Hakko Kirin Business Overview
- 6.7.3 Kyowa Hakko Kirin Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.7.4 Kyowa Hakko Kirin Recombinant Erythropoietin Product Portfolio
- 6.7.5 Kyowa Hakko Kirin Recent Developments
- 6.8 LG Life Sciences Ltd
- 6.8.1 LG Life Sciences Ltd Comapny Information
- 6.8.2 LG Life Sciences Ltd Business Overview
- 6.8.3 LG Life Sciences Ltd Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.8.4 LG Life Sciences Ltd Recombinant Erythropoietin Product Portfolio
- 6.8.5 LG Life Sciences Ltd Recent Developments
- 6.9 Amgen
- 6.9.1 Amgen Comapny Information
- 6.9.2 Amgen Business Overview
- 6.9.3 Amgen Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.9.4 Amgen Recombinant Erythropoietin Product Portfolio
- 6.9.5 Amgen Recent Developments
- 6.10 Roche
- 6.10.1 Roche Comapny Information
- 6.10.2 Roche Business Overview
- 6.10.3 Roche Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.10.4 Roche Recombinant Erythropoietin Product Portfolio
- 6.10.5 Roche Recent Developments
- 6.11 Johnson & Johnson
- 6.11.1 Johnson & Johnson Comapny Information
- 6.11.2 Johnson & Johnson Business Overview
- 6.11.3 Johnson & Johnson Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.11.4 Johnson & Johnson Recombinant Erythropoietin Product Portfolio
- 6.11.5 Johnson & Johnson Recent Developments
- 6.12 Sun Pharmaceutical Industries Ltd
- 6.12.1 Sun Pharmaceutical Industries Ltd Comapny Information
- 6.12.2 Sun Pharmaceutical Industries Ltd Business Overview
- 6.12.3 Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.12.4 Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Product Portfolio
- 6.12.5 Sun Pharmaceutical Industries Ltd Recent Developments
- 6.13 Teva Pharmaceutical Industries Ltd
- 6.13.1 Teva Pharmaceutical Industries Ltd Comapny Information
- 6.13.2 Teva Pharmaceutical Industries Ltd Business Overview
- 6.13.3 Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Revenue, Global Share and Gross Margin (2020-2025)
- 6.13.4 Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Product Portfolio
- 6.13.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 7 North America
- 7.1 North America Recombinant Erythropoietin Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America Recombinant Erythropoietin Market Size by Country (2020-2025)
- 7.3 North America Recombinant Erythropoietin Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe Recombinant Erythropoietin Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe Recombinant Erythropoietin Market Size by Country (2020-2025)
- 8.3 Europe Recombinant Erythropoietin Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant Erythropoietin Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific Recombinant Erythropoietin Market Size by Country (2020-2025)
- 9.3 Asia-Pacific Recombinant Erythropoietin Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America Recombinant Erythropoietin Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America Recombinant Erythropoietin Market Size by Country (2020-2025)
- 10.3 South America Recombinant Erythropoietin Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant Erythropoietin Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa Recombinant Erythropoietin Market Size by Country (2020-2025)
- 11.3 Middle East & Africa Recombinant Erythropoietin Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.